Assessment of the application for renewal of authorisation of GalliPro® (Bacillus subtilis DSM 17299) for chickens for fattening

EFSA Panel on Additives and Products or Substances used in Animal Feed (EFSA FEEDAP Panel), Vasileios Bampidis, Giovanna Azimonti, Maria de Lourdes Bastos, Henrik Christensen, Birgit Dusemund, Maryline Kouba, Mojca Kos Durjava, Marta López-Alonso, Secundino López Puente, Francesca Marcon, Baltasar Mayo, Alena Pechová, Mariana Petkova, Fernando Ramos, Yolanda Sanz, Roberto Edoardo Villa, Ruud Woutersen, Jaime Aguilera and Rosella Brozzi

Abstract

GalliPro® is the trade name for a feed additive based on viable cells of a strain of Bacillus subtilis intended for use as a zootechnical additive (gut flora stabiliser) in feed for chickens for fattening. The product is currently authorised for use in chickens for fattening. This opinion concerns the renewal of this authorisation. Bacillus subtilis is considered by EFSA to be suitable for the qualified presumption of safety (QPS) approach to establish the safety for the target species, consumers and the environment. The identity of the strain present in the additive was established and evidence was provided on the lack of toxigenic potential as well as acquired antibiotic resistance determinants to antibiotics of human and veterinary importance. Accordingly, this strain is presumed safe for the target species, consumers of products derived from animals fed the additive and the environment. Since no concerns are expected from other components of the additive, GalliPro® is considered safe for the target species, consumers and the environment. The applicant has provided evidence that the additive currently in the market complies with the existing conditions of authorisation. The FEEDAP Panel confirms its previous conclusions that GalliPro® is safe for the target species; consumers of products from animals fed the additive and the environment. GalliPro® should be considered a potential respiratory sensitiser. In the absence of data, the FEEDAP Panel cannot conclude on the potential of GalliPro® for skin and eyes irritancy and dermal sensitisation.

© 2019 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

Keywords: zootechnical additive, gut flora stabiliser, GalliPro®, Bacillus subtilis DSM 17299, safety, QPS, chickens for fattening

Requestor: European Commission
Question number: EFSA-Q-2016-00668
Correspondence: feedap@efs.europa.eu
Panel members: Giovanna Azimonti, Vasileios Bampidis, Maria de Lourdes Bastos, Henrik Christensen, Birgit Dusemund, Maryline Koub, Mojca Kos Durjava, Marta López-Alonso, Secundino López Puente, Francesca Marcon, Baltasar Mayo, Alena Pechová, Mariana Petkova, Fernando Ramos, Yolanda Sanz, Roberto Edoardo Villa and Ruud Woutersen.

Acknowledgements: The EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed) wishes to thank the following for the support provided to this scientific output: Lucilla Gregoretti, Jaume Galobart, Matteo Innocenti and Maria Vittoria Vettori.

Legal notice: Relevant information or parts of this scientific output have been blackened in accordance with the confidentiality requests formulated by the applicant pending a decision thereon by the European Commission. The full output has been shared with the European Commission, EU Member States and the applicant. The blackening will be subject to review once the decision on the confidentiality requests is adopted by the European Commission.

Suggested citation: EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), Bampidis V, Azimonti G, Bastos ML, Christensen H, Dusemund B, Koub M, Kos Durjava M, López-Alonso M, López Puente S, Marcon F, Mayo B, Pechová A, Petkova M, Ramos F, Sanz Y, Villa RE, Woutersen R, Aguilera J and Brozzi R, 2019. Scientific Opinion on the assessment of the application for renewal of authorisation of GalliPro® (*Bacillus subtilis* DSM 17299) for chickens for fattening. EFSA Journal 2019;17(4):5687, 10 pp. https://doi.org/10.2903/j.efsa.2019.5687

ISSN: 1831-4732

© 2019 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.

The EFSA Journal is a publication of the European Food Safety Authority, an agency of the European Union.
Table of contents

Abstract .................................................................................................................................................... 1
1. Introduction ................................................................................................................................... 4
   1.1. Background and Terms of Reference ......................................................................................... 4
   1.2. Additional information ............................................................................................................... 4
2. Data and methodologies ................................................................................................................. 5
   2.1. Data .............................................................................................................................................. 5
   2.2. Methodologies ................................................................................................................................5
3. Assessment .................................................................................................................................... 5
   3.1. Characterisation ............................................................................................................................. 5
      3.1.1. Characterisation of the additive ............................................................................................... 5
      3.1.2. Characterisation of the active agent ........................................................................................ 6
      3.1.3. Conditions of use ..................................................................................................................... 6
   3.2. Safety ........................................................................................................................................... 6
      3.2.1. Safety for the target species, consumers and the environment .................................................. 6
      3.2.2. Safety for the user ....................................................................................................................... 6
      3.2.3. Further evidence ....................................................................................................................... 6
      3.2.4. Efficacy ......................................................................................................................................... 7
   3.3. Post-market monitoring ................................................................................................................... 7
4. Conclusions .................................................................................................................................... 7
Documentation provided to EFSA/Chronology .............................................................................................. 7
References ................................................................................................................................................ 8
Abbreviations ............................................................................................................................................ 8
Appendix A – List of references retrieved from the literature search provided by the applicant to support safety of the additive ................................................................................................................................. 9
1. Introduction

1.1. Background and Terms of Reference

Regulation (EC) No 1831/2003\(^1\) establishes the rules governing the Community authorisation of additives for use in animal nutrition. In particular, Article 14 of that Regulation specifies that for products authorised according to Article 9, an application for renewal shall be submitted in accordance with Article 7, at the latest one year before the expiry date of the authorisation.

The European Commission received a request from Chr. Hansen A/S\(^2\) for renewal of the authorisation of the product GalliPro\(^3\) (\textit{Bacillus subtilis} DSM 17299\(^4\)), when used as a feed additive for chickens for fattening (category: zootechnical additive; functional group: gut flora stabiliser).

According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the application to the European Food Safety Authority (EFSA) as an application under Article 14(1) (renewal of an authorised feed additive). EFSA received directly from the applicant the technical dossier in support of this application. The particulars and documents in support of the application were considered valid by EFSA as of 7 December 2016.

According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and documents submitted by the applicant, shall undertake an assessment in order to determine whether the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the safety for the target animals, consumer, user and the environment and on the efficacy of the product GalliPro\(^5\) (\textit{Bacillus subtilis} DSM 17299), when used under the proposed conditions of use (see Section 3.1.3).

1.2. Additional information

EFSA has issued several opinions on the safety and efficacy of GalliPro\(^6\) for chickens for fattening and on its compatibility with coccidiostats (EFSA, 2006, 2007a, 2008, 2009, 2010). In 2011, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) produced an opinion on the modification to the formulation of GalliPro\(^7\) and on its compatibility with formic acid (EFSA FEEDAP Panel, 2011).

The product is currently authorised for use in chickens for fattening.\(^8\) It was originally authorised under the tradename 035 as a product containing a minimum guaranteed concentration of \textit{Bacillus subtilis} DSM 17299 of $1.6 \times 10^9$ colony forming units (CFU) per gram of additive, intended for use in feed for chickens for fattening at a minimum concentration of $8 \times 10^8$ CFU/kg feed and a maximum concentration of $1.6 \times 10^9$ CFU/kg feed. In 2011, the authorisation was amended to increase the minimum guaranteed concentration of \textit{Bacillus subtilis} DSM 17299 to $1.6 \times 10^{10}$ CFU/g of additive and to allow the simultaneous use with formic acid. In an amendment in 2012, the maximum concentration in feed was removed. Other amendments in 2010 and 2011 regarded the authorisation of use in the presence of the coccidiostats diclazuril, halofuginone, robenidine, decoquinate, narasin/nicarbazin, lasalocid sodium, maduramicin ammonium, monensin sodium, narasin, salinomycin sodium, semduramycin sodium.

\(^1\) Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in animal nutrition. OJ L 268, 18.10.2003, p. 29.

\(^2\) Chr. Hansen A/S, 10-12 Boege Alle, DK 2970, Hoersholm, Denmark.

\(^3\) The Applicant also markets the product under other trade names: 035, GalliPro\(^8\) Max, GalliPro\(^9\) 10.

\(^4\) Commission Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in animal nutrition. OJ L 268, 18.10.2003, p. 29.

\(^5\) The Applicant also markets the product under other trade names: 035, GalliPro\(^8\) Max, GalliPro\(^9\) 10.

\(^6\) Commission Regulation (EC) No 1137/2007 of 1 October 2007 concerning the authorisation of \textit{Bacillus subtilis} (O35) as a feed additive. OJ L 256, 2.10.2007, p. 5; Commission Regulation (EC) No 203/2009 of 16 March 2009 amending Regulation (EC) No 1137/2007 as regards the use of the feed additive \textit{Bacillus subtilis} (O35) in feed containing decoquinate and narasin/nicarbazin, OJ L 71, 17.3.2009, p. 11; Commission Regulation (EU) No 515/2010 of 15 June 201 amending Regulation (EC) No 1137/2007 as regards the use of the feed additive \textit{Bacillus subtilis} (O35) in feed containing lasalocid sodium, maduramicin ammonium, monensin sodium, narasin, salinomycin sodium and semduramycin sodium, OJ L 150, 16.6.2010, p. 44; Commission Implementing Regulation (EU) No 881/2011 of 2 September 2011 amending Regulation (EC) No 1137/2007 as regards the additive composition of the preparation of \textit{Bacillus subtilis} DSM 17299 (holder of authorisation Chr. Hansen A/S) and its use in feed containing formic acid; OJ L 228, 3.9.2011, p. 9; COMMISSION IMPLEMENTING REGULATION (EU) No 1018/2012 of 5 November 2012 amending Regulations (EC) No 232/2009, (EC) No 188/2007, (EC) No 186/2007, (EC) No 209/2008, (EC) No 1447/2006, (EC) No 316/2003, (EC) No 1811/2005, (EC) No 1288/2004, (EC) No 2148/2004, (EC) No 1137/2007, (EC) No 1293/2008, (EC) No 226/2007, (EC) No 1444/2006, (EC) No 1876/2006, (EC) No 1847/2003, (EC) No 2036/2005, (EC) No 492/2006, (EC) No 1200/2005, and (EC) No 1520/2007 as regards the maximum content of certain micro-organisms in complete feedingstuffs; OJ L 307, 7.11.2012, p. 56.

www.efsa.europa.eu/efsajournal

4 EFSA Journal 2019;17(4):5687
2. Data and methodologies

2.1. Data

The present assessment is based on data submitted by the applicant in the form of a technical dossier\(^6\) in support of the request for the renewal of the authorisation for the use of GalliPro\(^\circ\) (\textit{Bacillus subtilis} DSM 17299) as a feed additive.

The European Union Reference Laboratory (EURL) considered that the conclusions and recommendations reached in the previous assessment are valid and applicable for the current application.\(^7\)

2.2. Methodologies

The approach followed by the FEEDAP Panel to assess the safety and the efficacy of GalliPro\(^\circ\) (\textit{Bacillus subtilis} DSM 17299) is in line with the principles laid down in Regulation (EC) No 429/2008\(^8\) and the relevant guidance documents: Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance (EFSA FEEDAP Panel, 2012), Guidance on the renewal of the authorisation of feed additives (EFSA FEEDAP Panel, 2013) and Guidance on the assessment of the toxigenic potential of Bacillus species used in animal nutrition (EFSA FEEDAP Panel, 2014).

3. Assessment

The additive GalliPro\(^\circ\) consists of viable spores of \textit{Bacillus subtilis} DSM 17299 and is currently authorised as a zootechnical additive (gut flora stabiliser) in feed for chickens for fattening. The applicant is asking for the renewal of the authorisation.

3.1. Characterisation

3.1.1. Characterisation of the additive

GalliPro\(^\circ\) is currently authorised as a solid preparation with a minimum guaranteed concentration of \textit{B. subtilis} DSM 17299 of \(1.6 \times 10^{10}\) CFU/gram of additive.\(^9\)

The additive is composed of 3% spores concentrate, 96% carrier (limestone/calcium carbonate) and 1% of anticaking agent (Kieselgur). The applicant stated that no changes in the manufacturing process or composition of the additive have been introduced since the last authorisation. Compliance with specifications was confirmed by the analysis of three recent batches produced (range: \(2.2–2.3 \times 10^{10}\) CFU/g, average: \(2.3 \times 10^{10}\) CFU/g).\(^10\)

Data from the same batches confirmed compliance with specifications for total coliforms (\(< 10^3\) CFU/g), \textit{Escherichia coli} (\(< 10\) CFU/g), yeasts and filamentous fungi (\(< 10^3\) CFU/g), and \textit{Salmonella} spp. (absent in 25 g).\(^10\) Data from other three recent batches confirmed compliance with specifications for undesirable substances. Values were: aflatoxin B1 (\(< 0.64 \mu g/kg)\),\(^11\) mercury (0.0106–0.0146 mg/kg), lead (0.458–0.850 mg/kg), cadmium (0.033–0.092 mg/kg),\(^12\) arsenic (0.535–0.892 mg/kg).\(^12\)

The dusting potential of three batches of the additive was tested with a Heubach dustmeter and showed values in the range 2.3–2.5 g/m\(^3\).\(^13\)

\(^6\) FEED dossier reference: FAD-2016-0059.
\(^7\) The full report is available on the EURL website: https://ec.europa.eu/jrc/en/eurl/feed-additives/evaluation-reports/fad-2005-0021?search&form-return
\(^8\) Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC) No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
\(^9\) Technical dossier/Section II.
\(^10\) Technical dossier/Section II/Annex II.1.3b.
\(^11\) Limit of quantification.
\(^12\) Technical dossier/Section II/Annex II.1.4.1.
\(^13\) Technical dossier/Supplementary information July 2018/Annex II.1.5b.v2.
3.1.2. Characterisation of the active agent

The active agent of GalliPro® is deposited in the German Collection of Microorganisms and cell Cultures with the accession number DSM 17299.14 Strain identification was achieved by pulsed-field gel electrophoresis (PFGE) after cleavage with restriction enzymes. The lack of resistance to relevant antibiotics and of toxigenic potential have been demonstrated following the guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance (EFSA FEEDAP Panel, 2012) and the guidance on the assessment of the toxigenic potential of Bacillus species used in animal nutrition (EFSA FEEDAP Panel, 2014).

3.1.3. Conditions of use

GalliPro® is currently authorised in feed for chickens for fattening at the minimum inclusion level of $8 \times 10^8$ CFU/kg complete feedingstuff.

It is allowed to be used simultaneously with the coccidiostats: diclazuril, halofuginone, robenidine, decoquinate, narasin/nicarbazin, lasalocid sodium, maduramycin ammonium, monensin sodium, narasin, salinomycin sodium and semduramycin sodium, and with formic acid.

The applicant proposes to maintain the same conditions of use.

3.2. Safety

3.2.1. Safety for the target species, consumers and the environment

The bacterial species B. subtilis is considered by EFSA to be suitable for the qualified presumption of safety (QPS) approach to safety assessment (EFSA, 2007a,b; EFSA BIOHAZ Panel, 2017). This approach requires the identity of the active agent to be established and evidence that the strain lacks of toxigenic potential and does not show resistance to antibiotics of human and veterinary importance. The identity of the GalliPro® strain was established as B. subtilis and the lack of toxigenic potential and of acquired antibiotic resistance determinants to relevant antibiotics was established. Accordingly, this strain is considered by EFSA to be suitable for the QPS approach to safety and is presumed safe for the target species, consumers of products derived from animals fed the additive and the environment. Since no concerns are expected from other components of the additive, GalliPro® is also considered safe for the target species, consumers of products from animals fed the additive and the environment.

3.2.2. Safety for the user

In its original opinion (EFSA, 2006), the FEEDAP Panel concluded that the additive due to its proteinaceous nature may induce respiratory sensitisation.

The dustiness of the preparation tested indicated a potential for users to be exposed via inhalation. No additional information has been provided in this application. No data are available on skin/eye irritation or skin sensitisation. In the absence of data, the FEEDAP Panel cannot conclude on the potential of GalliPro® for skin and eyes irritancy and dermal sensitisation.

3.2.3. Further evidence

The applicant declares to have a post-market monitoring system in place and that no adverse effects or complaints have been reported by users of the product or workers handling it during production process.19

The applicant conducted a literature search on the safety of GalliPro® using several databases: Academic Onefile, Food Science Source, Agris and PubMed.20 The search included the terms:

---

14 Technical dossier/Supplementary information July 2018/Annex II.2.1.2a.v2.

19 Technical dossier/Section III.

20 Technical dossier/Supplementary information July 2018/Annexes III.3 and Supplementary information October 2018.
Bacillus subtilis, DSM 17299, GalliPro, safety, toxicity and adverse effect. The search covered the period 2007–2018 and identified 67 potential relevant publications (Appendix A). The majority of the experiments were not designed to assess the safety per se of the additive, but to investigate the effect(s) of the additive on zootechnical performance. Some included also health parameters (i.e. blood biochemistry, mortality), and one in particular investigated the immune response of Salmonella challenged chickens fed diets containing Gallipro®. The results did not evidence any adverse effect of the additive on the immune response of birds, either in challenged or non-contaminated birds (Sadeghi et al., 2015). A second study tested the effects of the supplementation of an additive containing the strain under assessment on tibial bone characteristics in chickens (e.g. thickness of the medial and lateral wall of the tibia, phosphorous content). Results did not reveal any adverse effect on the parameters measured.

Therefore, the FEEDAP Panel concludes that there is no new evidence that would lead the Panel to reconsider its previous conclusions on the safety of the product for target species, consumers, users and the environment under the authorised conditions of use.

3.2.4. Efficacy

The present application for renewal of the authorisation does not include a proposal for amending or supplementing the conditions of the original authorisation that would have an impact on the efficacy of the additive. Therefore, there is no need for assessing the efficacy of the additive in the context of the renewal of the authorisation.

3.3. Post-market monitoring

The FEEDAP Panel considers that there is no need for specific requirements for a post-market monitoring plan other than those established in the Feed Hygiene Regulation and Good Manufacturing Practice.

4. Conclusions

The applicant has provided evidence that the additive currently in the market complies with the existing conditions of authorisation.

The FEEDAP Panel confirms its previous conclusions that GalliPro® is safe for the target species, consumers of products from animals fed the additive and the environment. GalliPro® should be considered a potential respiratory sensitiser. In the absence of data, the FEEDAP Panel cannot conclude on the potential of GalliPro® for skin and eyes irritancy and dermal sensitisation.

Documentation provided to EFSA/Chronology

| Date     | Event                                                                 |
|----------|----------------------------------------------------------------------|
| 29/09/2016 | Dossier received by EFSA. GalliPro. Submitted by Chr. Hansen A/S |
| 24/10/2016 | Reception mandate from the European Commission                  |
| 07/12/2016 | Application validated by EFSA - Start of the scientific assessment |
| 07/03/2017 | Comments received from Member States                               |
| 10/10/2017 | Spontaneous submission of information by the applicant. Issues: safety for the consumer |
| 05/02/2018 | Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation (EC) No 1831/2003 – Scientific assessment suspended. Issues: characterisation, safety for target species, consumer, user and environment |
| 19/07/2018 | Reception of supplementary information from the applicant - Scientific assessment re-started |
| 12/10/2018 | Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation (EC) No 1831/2003 – Scientific assessment suspended Issues: Safety |
| 29/10/2018 | Reception of supplementary information from the applicant - Scientific assessment re-started |
| 01/04/2019 | Opinion adopted by the FEEDAP Panel. End of the Scientific assessment |

21 Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for feed hygiene. OJ L 35, 8.2.2005, p. 1.
References

EFSA (European Food Safety Authority), 2006. Opinion of the Scientific Panel on Additives and Products or Substances used in Animal Feed on the microbiological product "035", a preparation of Bacillus subtilis DSM 17299 as a feed additive for chickens for fattening in accordance with Regulation (EC) 1831/2003. EFSA Journal 2006;4(10):406, 11 pp. https://doi.org/10.2903/j.efsa.2006.406

EFSA (European Food Safety Authority), 2007a. Scientific Opinion of the Panel on Additives and Products or Substances used in animal feed (FEEDAP) on the compatibility of the microbial product 035, a preparation of Bacillus subtilis, with lasalocid sodium, maduramycin ammonium, monensin sodium, narasin, salinomycin sodium and semduramycin sodium. EFSA Journal 2007;5(10):575, 7 pp. https://doi.org/10.2903/j.efsa.2007.575

EFSA (European Food Safety Authority), 2007b. Opinion of the Scientific Committee on a request from EFSA on the introduction of a Qualified Presumption of Safety (QPS) approach for assessment of selected microorganisms referred to EFSA. EFSA Journal 2007;5(12):587, 16 pp. https://doi.org/10.2903/j.efsa.2007.587

EFSA (European Food Safety Authority), 2008. Scientific Opinion of the Panel on additives and products or substances used in animal feed (FEEDAP) on the compatibility of the microbial product 035 (Bacillus subtilis) with decoquinate and narasin/nicarbazin. EFSA Journal 2008;6(11):840, 7pp. https://doi.org/10.2903/j.efsa.2008.840

EFSA (European Food Safety Authority), 2009. Scientific Opinion of the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) on a request from the European Commission on the compatibility of the microbial products 035 (Bacillus subtilis) with lasalocid sodium, maduramycin ammonium, monensin sodium, narasin, salinomycin sodium and semduramycin sodium. EFSA Journal 2009;7(6):1096, 7 pp. https://doi.org/10.2903/j.efsa.2009.1096

EFSA (European Food Safety Authority), 2010. EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP); Scientific Opinion on the compatibility of the microbial product 035 (Bacillus subtilis) with lasalocid sodium, maduramycin ammonium, monensin sodium, narasin, salinomycin sodium and semduramycin sodium. EFSA Journal 2010;8(3):1552, 7 pp. https://doi.org/10.2903/j.efsa.2010.1552

EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), Ricci A, Allende A, Bolton D, Chernaly M, Davies R, Girones R, Herman L, Koutsoumanis K, Lindqvist R, Nørrung B, Robertson L, Ru G, Sanaa M, Simmons M, Skandamis P, Snary E, Speybroeck N, Ter Kuile B, Threlfall J, Wahlström H, Cocconcelli PS, Klein G (deceased), Prieto Maradona M, Querol A, Peixe L, Suarez JE, Sundh I, Vlak JM, Aguillera-Gomez M, Barizzone F, Brozzi R, Correia S, Heng L, Istace F, Lythgo C and Fernandez Escamez PS, 2017. Scientific Opinion on the update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA. EFSA Journal 2017;15(3):4664, 177 pp. https://doi.org/10.2903/j.efsa.2017.4664

EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2011. Scientific Opinion on the modification to the formulation of GalliPro® and compatibility with formic acid. EFSA Journal 2011;9(3):2112, 7 pp. https://doi.org/10.2903/j.efsa.2011.2112

EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2012. EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP); Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance. EFSA Journal 2012;10(6):2740, 10 pp. https://doi.org/10.2903/j.efsa.2012.2740

EFSA FEEDAP Panel (Panel on Additives and Products or Substances used in Animal Feed), 2013. Guidance on the renewal of the authorisation of feed additives. EFSA Journal 2013;11(10):3431, 8 pp. https://doi.org/10.2903/j.efsa.2013.3431

EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2014. Guidance on the assessment of the toxigenic potential of Bacillus species used in animal nutrition. EFSA Journal 2014;12(5):3665, 10 pp. https://doi.org/10.2903/j.efsa.2014.3665

Sadeghi AA, Shawrang P and Shakorzadeh S, 2015. Immune response of salmonella challenged broiler chickens fed diets containing Gallipro®, a Bacillus subtilis probiotic. Probiotics Antimicrobial Proteins, 7, 24–30. https://doi.org/10.1007/s12602-014-9175-1

Abbreviations

CFU  colony forming unit
EURL  European Union Reference Laboratory
FEEDAP  EFSA Panel on Additives and Products or Substances used in Animal Feed
PFGE  pulsed-field gel electrophoresis
QPS  Qualified Presumption of Safety
Appendix A – List of references retrieved from the literature search provided by the applicant to support safety of the additive

Alexopoulos C, Georgoulakis IE, Tzivara A, Kritas SK, Siochu A, Kyriakis SC, 2004. Field evaluation of the efficacy of a probiotic containing *Bacillus licheniformis* and *Bacillus subtilis* spores, on the health status and performance of sows and their litters. Journal of Animal Physiology and Animal Nutrition (Berl), 88, 381-92.

Al-Sagan, Ahmed A. Abudabos, Alaeldein M, 2018. Effect of eubiotic administration to broiler’s feed on intestinal morphology and microbiology under *Clostridium perfringens* challenge. *Indian Journal of Animal Research*., 52, p824-828. 5p. https://doi.org/10.18805/ijar.10774

Azarin H, Aramil MS, Imanpour MR, Rajabpour M, 2015. Effect of a Probiotic Containing *Bacillus licheniformis* and *Bacillus subtilis* and Ferroin Solution on Growth Performance, Body Composition and Haematological Parameters in Kutum (*Rutilus frisii kutum*) Fry. Probiotics Antimicrob Proteins, 7, 31-37. https://doi.org/10.1007/s12602-014-9180-4

Baur X, Bakehe P, 2014. Allergens causing occupational asthma: an evidence-based evaluation of the literature. *International Archives of Occupational and Environmental Health*, 87, 339–363. https://doi.org/10.1007/s00420-013-0866-9

Cramer TA, Kim HW, Chao Y, Wang W, Cheng HW, Kim YHB., 2018. Effects of probiotic (*Bacillus subtilis*) supplementation on meat quality characteristics of breast muscle from broilers exposed to chronic heat stress. *Poultry Science*, 97, 3358-3368. https://doi.org/10.3382/ps/pey176

Deng B, Wu J, Li X, Men X, Xu Z., 2017. Probiotics and Probiotic Metabolic Product Improved Intestinal Function and Ameliorated LPS-Induced Injury in Rats. *Current Microbiology*, 74, 1306-1315. https://doi.org/10.1007/s00284-017-1318-7

Egamberdieva D, Wirth SJ, Shurigin VV, Hashem A, Abd Allah EF., 2017. Endophytic Bacteria Improve Plant Growth, Symbiotic Performance of Chickpea (*Cicer arietinum* L.) and Induce Suppression of Root Rot Caused by *Fusarium solani* under Salt Stress. Frontiers in Microbiology, 8, 1887. https://doi.org/10.3389/fmicb.2017.01887

Fan Y, Zhao L, Ma Q, Li X, Shi H, Zhou T, Zhang J, Ji C., 2013. Effects of *Bacillus subtilis* ANSB060 on growth performance, meat quality and aflatoxin residues in broilers fed moldy peanut meal naturally contaminated with aflatoxins. *Food and Chemical Toxicology*, 59, 748–753.

Fan Y, Zhao L, Ji C, Li X, Jia R, Xi L, Zhang J, Ma Q., 2015. Protective Effects of Bacillus subtilis ANSB060 on Serum Biochemistry, Histopathological Changes and Antioxidant Enzyme Activities of Broilers Fed Moldy Peatmeal Naturally Contaminated with Aflatoxins. *Toxins (Basel)*, 7, 3330–3343. https://doi.org/10.3390/toxins7083330

Fathi M, Abdelsalam M, Al-Homidan I, Ebeid T, El-Zarei M, Abou-Emera O., 2017. Effect of probiotic supplementation and genotype on growth performance, carcass traits, hematological parameters and immunity of growing rabbits under hot environmental conditions. *Animal Science Journal*, 88, 1644-1650.

Foligné B, Peys E, Vandenkerckhove J, Van Hemel J, Dewulf J, Breton J, Pot B, 2012. Spores from two distinct colony types of the strain *Bacillus subtilis* PB6 substantiate anti-inflammatory probiotic effects in mice. *Clinical Nutrition*, 31, 987-994. https://doi.org/10.1016/j.clnu.2012.05.016

Goodarzi Boroojeni F, Senz M, Kozłowski K, Boros D, Wisniewska M, Rose D, Manner K, Zentek J, 2017. The effects of fermentation and enzymatic treatment of pea on nutrient digestibility and growth performance of broilers. Animal, 11, 1698-707.

Hanifi A, Culpepper T, Mai V, Anand A, Ford AL, Ukhanova M, Christman M, Tompkins TA, Dahl WJ., 2015. Evaluation of *Bacillus subtilis* R0179 on gastrointestinal viability and general wellness: a randomised, double-blind, placebo-controlled trial in healthy adults. Beneficial Microbes, 6, 19–27. https://doi.org/10.3920/bm2014.0031

Hsia CH, Shen MC, Lin JS, Wen YK, Hwang KL, Cham TM, Yang NC, 2009. Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects. *Nutrition Research*, 29, 190–196. https://doi.org/10.1016/j.nutres.2009.01.009

Huang J-M, La Ragione RM, Nunez A, Cutting SM, 2008. Immunostimulatory activity of Bacillus spores. *FEMS Immunology & Medical Microbiology*, 53, p195-203. 9p. 1 Color Photograph, 3 Charts, 4 Graphs. https://doi.org/10.1111/j.1574-695x.2008.00415.x

Inomata N, Osuna H, Kawano K, Yamaguchi J, Yanagimachi M, Matsukura S, Ikezawa Z, 2007. Late-onset anaphylaxis after ingestion of *Bacillus subtilis*-fermented soybeans (Natto): clinical review of 7 patients. *Allergology International*, 56, 257-261.
Kritas SK, Govaris A, Christodouloupolos G, Burriel ARJ, 2006. Effect of *Bacillus licheniformis* and *Bacillus subtilis* (BioPlus 2B) supplementation of ewe's feed on sheep milk production and young lamb mortality. Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine, 53, 170–173.

Kurtoglu V, Kurtoglu F, Seker E, Coskun B, Balevi T, Polat ES, 2004. Effect of probiotic (BioPlus 2B) supplementation on laying hen diets on yield performance and serum and egg yolk cholesterol. Food Additives and Contaminants, 21, 817–823.

Latorre JD, Hernandez-Velasco X, Kogut MH, Vicente JL, Wolfenden R, Wolfenden A, Hargis BM, Kuttappan VA, Tellez G, 2014. Role of a *Bacillus subtilis* Direct-Fed Microbial on Digesta Viscosity, Bacterial Translocation, and Bone Mineralization in Turkey Poult Fed with a Rye-Based Diet. Frontiers in Veterinary Science, 1, 26. https://doi.org/10.3389/fvets.2014.00026

Lee YJ, Kim JE, Kwak MH, Go J, Son HJ, Kim DS, Kang BC, Lee HS, Hwang DY., 2014. Toxicity of fermented soybean product (cheonggukjang) manufactured by mixed culture of *Bacillus subtilis* MC31 and *Lactobacillus sakei* 383 on liver and kidney of ICR mice. Laboratory Animal Research, 30, 54–63. https://doi.org/10.10562/lar.2014.30.2.54

Madsen AM, 2011. Occupational exposure to microorganisms used as biocontrol agents in plant production. Front Biosci (Schol Ed), 3, 606-20. Review.

Moore T, Globa L, Pustovyy O, Vodyanoy V, Sorokulova I, 2014. Oral administration of *Bacillus subtilis* strain BS83 can prevent heat stress-related adverse effects in rats. Journal of Applied Microbiology, 117, 1463–1471. https://doi.org/10.1111/jam.12606

Nguyen AT, Nguyen DV, Tran MT, Nguyen LT, Nguyen AH, Phan TN, 2015. Isolation and characterization of *Bacillus subtilis* CH16 strain from chicken gastrointestinal tracts for use as a feed supplement to promote weight gain in broilers. Letters in Applied Microbiology, 60, 580–588. https://doi.org/10.1111/lam.12411

Ramanaidu K, Cutler GC, 2013. Different toxic and hormetic responses of *Bombus impatiens* to *Beauveria bassiana*, *Bacillus subtilis* and spirotetramat. Pest Management Science, 69, 949–954. https://doi.org/10.1002/ps.3456

Sadeghi AA, Shawrang P, Shakorzadeh S, 2015. Immune Response of *Salmonella* Challenged Broiler Chickens Fed Diets Containing Gallipro®, a *Bacillus subtilis* Probiotic. Probiotics and Antimicrobial Proteins, 7, 24–30. https://doi.org/10.1007/s12602-014-9175-1

Sorokulova I, Globa L, Pustovyy O, Vodyanoy V, 2016. Prevention of Heat Stress Adverse Effects in Rats by *Bacillus subtilis* Strain. Journal of Visualized Experiments, 11, e54122. https://doi.org/10.3791/54122

Stickel F, Droz S, Patensenker E, Bögl-Stuber K, Aebi B, Leib SL, 2009. Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with *Bacillus subtilis*. Journal of Hepatology, 50, 111-7. https://doi.org/10.1016/j.jhep.2008.08.017

Sun C, Geng L, Wang M, Shao G, Liu Y, Shu C, Zhang J, 2017. No adverse effects of transgenic maize on population dynamics of endophytic *Bacillus subtilis* strain B916-gfp. Microbiologysopen, 6, e00404. https://doi.org/10.1002/mbo3.404

Yu XM, Yu T, Yin GH, Dong QL, An M, Wang HR, Ai CX, 2015. Glyphosate biodegradation and potential soil bioremediation by *Bacillus subtilis* strain Bs-15. Genetics and Molecular Research, 14, 14717–14730. https://doi.org/10.4238/2015.November.18.37

Yun JH, Cho DH, Lee B, Kim HS, Chang YK, 2018. Application of biosurfactant from *Bacillus subtilis* C9 for controlling cladoceran grazers in algal cultivation systems. Scientific Reports, 8, 5365. https://doi.org/10.1038/s41598-018-23535-8

Zeng J, Wang CT, Zhang FS, Qi F, Wang SF, Ma S, Wu TJ, Tian H, Tian ZT, Zhang SL, Qu Y, Liu LY, Li YZ, Cui S, Zhao HL, Du QS, Ma Z, Li CH, Li Y, Si M, Chu YF, Meng M, Ren HS, Zhang JC, Jiang JJ, Ding M, Wang YP, 2016. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial. Intensive Care Medicine, 42, 1018–1028. https://doi.org/10.1007/s00134-016-4303-x

Zouari R, Hamden K, El Feki A, Chaabouni K, Makni-Ayadi F, Sallemi F, Elouze-Chaabouni S, Ghribi Aydi D., 2017. Evaluation of *Bacillus subtilis* SPB1 biosurfactant effects on hyperglycemia, angiotensin I-converting enzyme (ACE) activity and kidney function in rats fed on high-fat-high-fructose diet. Archives of Physiology and Biochemistry, 123, 112–120. https://doi.org/10.1080/13813455.2016.1261902